Compare AbCellera Biologics Inc (ABCL) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs MINISO Group Holding Ltd — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while MINISO Group Holding Ltd trades at $11.8 (market cap $3.52B). The key difference: MINISO Group Holding Ltd is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 5.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MNSO | |
|---|---|---|
Market Cap | $2.35B | $3.52B |
Sector | Health | Technology |
52-Week High | $8.12 | $26.63 |
52-Week Low | $2.78 | $11.30 |
Enterprise Value | $1.99B | $4.19B |
Dividend Yield | — | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MNSO trades at $11.90, up 1.54% today, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth of 28.5% year-over-year, and announced a HK$2 billion share repurchase program on June 29, 2026. Valuation ratios appear reasonable with a P/E of 12.11 and P/S of 1.1, while profitability metrics show a net income margin of 8.98% and ROE of 18.88%.
The outlook is cautiously optimistic given earnings momentum and shareholder-friendly actions, but risks include margin pressure from rising expenses and competitive threats. Analyst sentiment is positive with 75% buy ratings, though technical indicators suggest near-term resistance. Investors should weigh solid fundamentals against bearish price trends for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
